WuXi Biologics (Cayman) Inc. (2269.HK)
HKD 17.08
(-1.27%)
HKD 17.08
(-1.27%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 4.66 Billion | 5.54 Billion | 3.43 Billion | 1.88 Billion | 1.2 Billion | 761.6 Million |
| Net Income | 4.17 Billion | 5.35 Billion | 3.99 Billion | 1.96 Billion | 1.12 Billion | 737.72 Million |
| Depreciation & Amortization | 1.16 Billion | 800.67 Million | 481.78 Million | 303 Million | 221.36 Million | 143.77 Million |
| Deferred income taxes | - | - | -567.11 Million | -221.85 Million | -64.52 Million | - |
| Stock-based compensation | 1.42 Billion | 1.29 Billion | 577.95 Million | 284.17 Million | 203.93 Million | 128.37 Million |
| Change in working capital | -896.34 Million | -974.47 Million | -963.32 Million | -367.06 Million | -216.06 Million | -245.73 Million |
| Other non-cash items | -82.88 Million | -876.68 Million | -45.12 Million | -74.94 Million | -63.27 Million | -2.52 Million |
| Investing Cash Flow | -3.22 Billion | -5.9 Billion | -9.6 Billion | -7.21 Billion | -4.49 Billion | -416.07 Million |
| Investments in PPE | -4.23 Billion | -5.86 Billion | -6.52 Billion | -6.02 Billion | -3.23 Billion | -1.83 Billion |
| Acquisitions | - | -131.48 Million | -2.53 Billion | -155.23 Million | -300.82 Million | 489.89 Million |
| Investment purchases | -15.08 Billion | -10.77 Billion | -59.3 Billion | -20.35 Billion | -4.64 Billion | -1.05 Billion |
| Sales/Maturities of investments | 15.63 Billion | 10.48 Billion | 58.24 Billion | 19.25 Billion | 3.91 Billion | 2.33 Billion |
| Other Investing Activities | 41.44 Million | 377.56 Million | 512.79 Million | 67.1 Million | -230.45 Million | -353.07 Million |
| Financing Cash Flow | 1.96 Billion | -2.59 Billion | 8.2 Billion | 6.56 Billion | 5.41 Billion | 3.2 Billion |
| Debt repayment | -704.74 Million | -2.56 Billion | -728.26 Million | -300.78 Million | -140 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -916.91 Million | -2.8 Billion | -2.51 Billion | - | - | - |
| Common Stock Issuance | 26.15 Million | 36.18 Million | 11.03 Billion | 5.64 Billion | 3.59 Billion | 3.22 Billion |
| Other Financing Activities | 3.89 Billion | 2.73 Billion | 419.53 Million | 1.21 Billion | 1.95 Billion | -18.63 Million |
| Accounts receivables | -1.03 Billion | -1.49 Billion | -1.44 Billion | -1.4 Billion | -649.52 Million | -463.58 Million |
| Accounts payables | - | 1.49 Billion | 1.44 Billion | 1.4 Billion | 649.52 Million | - |
| Inventory | 442.46 Million | -498.12 Million | -783.18 Million | -704.52 Million | -94 Million | -95.68 Million |
| Other working capital | 178.41 Million | -476.35 Million | -180.14 Million | 337.45 Million | -122.06 Million | -150.05 Million |
| Cash at beginning of period | 6.39 Billion | 9 Billion | 7.09 Billion | 6.2 Billion | 4.08 Billion | 503.88 Million |
| Cash at end of period | 9.66 Billion | 6.39 Billion | 9 Billion | 7.09 Billion | 6.2 Billion | 4.08 Billion |
| Capital Expenditure | -4.23 Billion | -5.86 Billion | -6.52 Billion | -6.02 Billion | -3.23 Billion | -1.83 Billion |
| Effect of forex changes on cash | -125.99 Million | 350.11 Million | -131.5 Million | -340.39 Million | -5.87 Million | 28.15 Million |
| Net cash flow / Change in cash | 3.27 Billion | -2.6 Billion | 1.9 Billion | 890.23 Million | 2.12 Billion | 3.58 Billion |
| Free Cash Flow | 437.19 Million | -326.71 Million | -3.09 Billion | -4.14 Billion | -2.02 Billion | -1.06 Billion |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 749.54 Million | 749.54 Million | 566.52 Million | 4.17 Billion | 566.52 Million | 1.13 Billion |
| Depreciation & Amortization | 391.89 Million | 391.89 Million | - | 1.16 Billion | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 345.07 Million | 345.07 Million | 320.4 Million | 1.42 Billion | 320.4 Million | 391.36 Million |
| Change in working capital | - | - | - | -896.34 Million | - | - |
| Other non-cash items | -835.44 Million | -835.44 Million | -886.92 Million | -82.88 Million | -886.92 Million | -1.52 Billion |
| Investing Cash Flow | -191.26 Million | -191.26 Million | - | -3.22 Billion | - | - |
| Investments in PPE | -933.69 Million | -933.69 Million | - | -4.23 Billion | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | -15.08 Billion | - | - |
| Sales/Maturities of investments | - | - | - | 15.63 Billion | - | - |
| Other Investing Activities | 742.42 Million | 742.42 Million | - | 41.44 Million | - | - |
| Financing Cash Flow | -737.79 Million | -737.79 Million | - | 1.96 Billion | - | - |
| Debt repayment | - | - | - | -704.74 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -617.19 Million | -617.19 Million | - | -916.91 Million | - | - |
| Common Stock Issuance | - | - | - | 26.15 Million | - | - |
| Other Financing Activities | -120.59 Million | -120.59 Million | - | 3.89 Billion | - | - |
| Accounts receivables | - | - | - | -1.03 Billion | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | 442.46 Million | - | - |
| Other working capital | - | - | - | 178.41 Million | - | - |
| Cash at beginning of period | - | - | - | 6.39 Billion | - | - |
| Cash at end of period | -258.15 Million | -258.15 Million | - | 9.66 Billion | - | 391.36 Million |
| Capital Expenditure | -933.69 Million | -933.69 Million | - | -4.23 Billion | - | - |
| Effect of forex changes on cash | 19.83 Million | 19.83 Million | - | -125.99 Million | - | - |
| Net cash flow / Change in cash | -258.15 Million | -258.15 Million | - | 3.27 Billion | - | 391.36 Million |
| Free Cash Flow | -282.63 Million | -282.63 Million | - | 437.19 Million | - | 391.36 Million |
2443
UUU
RPAC
GMBLP
GLOBAL
SMMT